Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination

Vaccine

Volumn 29, Issue 47, 2011, Pages 8656-8660

  Winnock, M ^a   Bani Sadr, F ^b   Pambrun, E ^a   Loko, M A ^a   Lascoux Combe, C ^c   Garipuy, D ^d   Rosenthal, E ^e   Carrieri, P ^f   Dabis, F ^a   Salmon, D ^b  

^a INSERM   (France)

^b Université Paris Descartes ^*  (France)

^c SAINT LOUIS HOSPITAL   (France)

^d hopital Joseph Ducuing   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

Author keywords

HAV and HBV vaccination; Hepatitis A immunity; Hepatitis B immunity; HIV HCV coinfection

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS A VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; EDUCATION; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 82455217330     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.125     Document Type: Article

References (25)

1. Tedaldi E.M., Baker R.K., Moorman A.C., Wood K.C., Fuhrer J., McCabe R.E., et al. B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004, 38:1478-1484.
2. Alberti A., Clumeck N., Collins S., Gerlich W., Lundgren J., Palu G., et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
3. Kahn J. Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Clin Infect Dis 2002, 35:1382-1387.
4. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
5. Lacombe K., Boyd A., Desvarieux M., Serfaty L., Bonnord P., Gozlan J., et al. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. AIDS 2007, 21:2546-2549.
6. Fonquernie L., Meynard J.L., Charrois A., Delamare C., Meyohas M.C., Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001, 32:297-299.
7. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286-290.
8. Rockstroh J.K., Bhagani S., Benhamou Y., Bruno R., Mauss S., Peters L., et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
9. Loko M.A., Salmon D., Carrieri P., Winnock M., Mora M., Merchadou L., et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010, 10:303.
10. Cruciani M., Mengoli C., Serpelloni G., Lanza A., Gomma M., Nardi S., et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009, 27:17-22.
11. Fonseca M.O., Pang L.W., de Paula Cavalheiro N., Barone A.A., Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902-2908.
12. Buxton J.A., Kim J.H., Hepatitis A., hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008, 19:197-202.
13. Keeffe E.B., Iwarson S., McMahon B.J., Lindsay K.L., Koff R.S., Manns M., et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998, 27:881-886.
14. Kramer E.S., Hofmann C., Smith P.G., Shiffman M.L., Sterling R.K. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci 2009, 54:2016-2025.
15. Wiedmann M., Liebert U.G., Oesen U., Porst H., Wiese M., Schroeder S., et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000, 31:230-234.
16. Leroy V., Bourliere M., Durand M., Abergel A., Tran A., Baud M., et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol Hepatol 2002, 14:485-489.
17. Rey D., Krantz V., Partisani M., Schmitt M.P., Meyer P., Libbrecht E., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161-1165.
18. Chakvetadze C., Bani-Sadr F., Le Pendeven C., Lescure F.X., Fontaine C., Galperine T., et al. Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis 2010, 50:1184-1186.
19. Gandhi R.T., Wurcel A., Lee H., McGovern B., Shopis J., Geary M., et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435-1441.
20. Arteaga A., Carrasco-Garrido P., de Andres A.L., de Miguel A.G., Jimenez-Garcia R. Trends of hepatitis A hospitalizations and costs associated with the hospitalization in Spain (2000-2005). J Viral Hepat 2009, 16:286-291.
21. Siddiqui F., Mutchnick M., Kinzie J., Peleman R., Naylor P., Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001, 96:858-863.
22. Hernandez B., Hasson N.K., Cheung R. Hepatitis C performance measure on hepatitis A and B vaccination: missed opportunities?. Am J Gastroenterol 2009, 104:1961-1967.
23. Shim M., Khaykis I., Park J., Bini E.J. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005, 42:688-695.
24. Shire N.J., Welge J.A., Sherman K.E. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Vaccine 2006, 24:272-279.
25. Launay O., Grabar S., Gordien E., Desaint C., Jegou D., Abad S., et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008, 49:272-275.